Patents by Inventor Shanshan NING

Shanshan NING has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ISOLATED ANTIGEN-BINDING PROTEIN AND APPLICATION THEREOF
    Publication number: 20220356259
    Abstract: An isolated antigen-binding protein, having one or more of the following properties: 1) capable of binding to human and monkey-derived GITR proteins at a KD value of 7×10?12 or below, wherein the KD value is measured by BLI method; 2) capable of stimulating immune cell proliferation; 3) capable of stimulating immune cells to secrete IFN-?, wherein the secretion is measured in T cell viability assay; 4) capable of inhibiting tumor growth and/or tumor cell proliferation; 5) capable of activating GITR signaling pathway; 6) capable of inhibiting the binding of GITR to GITRL.
    Type: Application
    Filed: July 16, 2020
    Publication date: November 10, 2022
    Inventors: Xin ZHANG, Ting XU, Hui MA, Yangyang YUAN, Shanshan NING, Shilong FU, Xiaolong PAN, Liyao ZHOU, Meng ZHAO, Erxia SHI
  • PROTEINACEOUS HETERODIMER AND USE THEREOF
    Publication number: 20220227827
    Abstract: Proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
    Type: Application
    Filed: March 24, 2020
    Publication date: July 21, 2022
    Applicant: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting XU, Jianjian PENG, Kai FU, Shilong FU, Xiaolong PAN, Jian DING, Shanshan NING, Liyao ZHOU
  • IL-10 EGFR antibody fusion protein and uses thereof
    Patent number: 11357826
    Abstract: The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: June 14, 2022
    Assignee: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting Xu, Yan Luan, Jianjian Peng, Shuli Ma, Meng Zhao, Xiaoxiao Wang, Hui Ma, Shilong Fu, Xiaolong Pan, Shanshan Ning
  • Fully human antibody against human CD 137
    Patent number: 10875926
    Abstract: Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: December 29, 2020
    Assignee: Dingfu Biotarget Co., Ltd.
    Inventors: Ting Xu, Yan Luan, Xiaoxiao Wang, Jianjian Peng, Shuli Ma, Hui Ma, Xiaolong Pan, Shilong Fu, Shanshan Ning, Yeqiong Fei, Meng Zhao
  • Anti-OX40 antibody and application thereof
    Patent number: 10624974
    Abstract: The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: April 21, 2020
    Assignee: Dingfu Biotarget Co., Ltd.
    Inventors: Ting Xu, Yan Luan, Xiaoxiao Wang, Jianjian Peng, Shuli Ma, Hui Ma, Xiaolong Pan, Shilong Fu, Shanshan Ning, Yeqiong Fei, Meng Zhao
  • Proteinaceous Complexes and Uses Thereof
    Publication number: 20200069773
    Abstract: The present disclosure provides proteinaceous complexes, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous complexes, methods for producing the proteinaceous complexes, and uses thereof.
    Type: Application
    Filed: August 21, 2019
    Publication date: March 5, 2020
    Applicant: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting XU, Yan LUAN, Jianjian PENG, Shuli MA, Meng ZHAO, Xiaoxiao WANG, Hui MA, Shilong FU, Xiaolong PAN, Shanshan NING
  • Proteinaceous heterodimer and use thereof
    Patent number: 10471124
    Abstract: The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: November 12, 2019
    Assignee: DINGFU BIOTARGET CO., LTD.
    Inventors: Ting Xu, Yan Luan, Jianjian Peng, Shuli Ma, Meng Zhao, Xiaoxiao Wang, Hui Ma, Shilong Fu, Xiaolong Pan, Shanshan Ning
  • Anti-OX40 Antibody And Application Thereof
    Publication number: 20180339059
    Abstract: The present application provides an anti-OX40 human antibody. In particular, a human antibody specifically binding to OX40 is obtained with yeast display screening, and the affinity of the antibody is improved with affinity maturation. The present application also provides a use of the antibody for the prevention or treatment of tumors.
    Type: Application
    Filed: October 15, 2015
    Publication date: November 29, 2018
    Inventors: Ting XU, Yan LUAN, Xiaoxiao WANG, Jianjian PENG, Shull MA, Hui MA, Xiaolong PAN, Shilong FU, Shanshan NING, Yeqiong FEI, Meng ZHAO
  • Fully Human Antibody Against Human CD137 And Use Thereof
    Publication number: 20180282422
    Abstract: Disclosed are a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof. a fully human monoclonal antibody specifically binding to a CD137 or an antigen binding portion thereof. On one hand, provided are a CDR/variable region sequence of the antibody and an encoding nucleic acid sequence thereof; on the other hand, provided is a method for treating diseases using the antibody or the antigen binding portion thereof.
    Type: Application
    Filed: September 22, 2015
    Publication date: October 4, 2018
    Inventors: Ting XU, Yan LUAN, Xiaoxiao WANG, Jianjian PENG, Shuli MA, Hui MA, Xiaolong PAN, Shilong FU, Shanshan NING, Yeqiong FEI, Meng ZHAO
  • PROTEINACEOUS HETERODIMER AND USE THEREOF
    Publication number: 20170340708
    Abstract: The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.
    Type: Application
    Filed: November 10, 2015
    Publication date: November 30, 2017
    Inventors: Ting XU, Yan LUAN, Jianjian PENG, Shuli MA, Meng ZHAO, Xiaoxiao WANG, Hui MA, Shilong FU, Xiolong PAN, Shanshan NING